Resistance Studies of a Dithiazol Analogue, DBPR110, as a Potential Hepatitis C Virus NS5A Inhibitor in Replicon Systems

Hepatitis C virus (HCV), a member of the Flaviviridae family, affects approximately 3% of the world's population and is becoming the leading cause of liver disease in the world. Therefore, the development of novel or more effective treatment strategies to treat chronic HCV infection is urgently...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lin, Hui-Mei, Wang, Jing-Chyi, Hu, Han-Shu, Wu, Pei-Shan, Wang, Wen-Hung, Wu, Su-Ying, Yang, Chi-Chen, Yeh, Teng-Kuang, Hsu, Tsu-An, Jiaang, Weir-Torn, Chao, Yu-Sheng, Chern, Jyh-Haur, Yueh, Andrew
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2013
Gaiak:
Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553732/
https://ncbi.nlm.nih.gov/pubmed/23165461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01403-12
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak